WO2022160931A1 - Dérivé de pyridopyrimidine, son procédé de préparation et son utilisation - Google Patents
Dérivé de pyridopyrimidine, son procédé de préparation et son utilisation Download PDFInfo
- Publication number
- WO2022160931A1 WO2022160931A1 PCT/CN2021/135230 CN2021135230W WO2022160931A1 WO 2022160931 A1 WO2022160931 A1 WO 2022160931A1 CN 2021135230 W CN2021135230 W CN 2021135230W WO 2022160931 A1 WO2022160931 A1 WO 2022160931A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- cycloalkyl
- ethyl
- alkoxy
- general formula
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 150000008518 pyridopyrimidines Chemical class 0.000 title abstract description 4
- 150000003839 salts Chemical class 0.000 claims abstract description 40
- 101100404726 Arabidopsis thaliana NHX7 gene Proteins 0.000 claims abstract description 24
- 102000057028 SOS1 Human genes 0.000 claims abstract description 24
- 108700022176 SOS1 Proteins 0.000 claims abstract description 24
- 101100197320 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) RPL35A gene Proteins 0.000 claims abstract description 24
- 101150100839 Sos1 gene Proteins 0.000 claims abstract description 24
- 239000003814 drug Substances 0.000 claims abstract description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 8
- 239000003112 inhibitor Substances 0.000 claims abstract description 3
- 150000001875 compounds Chemical class 0.000 claims description 84
- -1 cyano, amino Chemical group 0.000 claims description 69
- 125000000623 heterocyclic group Chemical group 0.000 claims description 57
- 229910052736 halogen Inorganic materials 0.000 claims description 38
- 150000002367 halogens Chemical class 0.000 claims description 38
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 36
- 125000003118 aryl group Chemical group 0.000 claims description 34
- 125000001424 substituent group Chemical group 0.000 claims description 33
- 125000000217 alkyl group Chemical group 0.000 claims description 24
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 21
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 19
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 18
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 16
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 16
- 125000004429 atom Chemical group 0.000 claims description 15
- 125000003545 alkoxy group Chemical group 0.000 claims description 14
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 13
- 125000001072 heteroaryl group Chemical group 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 7
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims description 7
- 125000004122 cyclic group Chemical group 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 7
- 239000001257 hydrogen Substances 0.000 claims description 6
- 230000001404 mediated effect Effects 0.000 claims description 6
- 230000035772 mutation Effects 0.000 claims description 6
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 5
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 5
- 201000002528 pancreatic cancer Diseases 0.000 claims description 5
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 5
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 4
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 4
- 206010014733 Endometrial cancer Diseases 0.000 claims description 4
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 4
- 239000004593 Epoxy Substances 0.000 claims description 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 4
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 4
- 208000034578 Multiple myelomas Diseases 0.000 claims description 4
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 4
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 206010038389 Renal cancer Diseases 0.000 claims description 4
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 4
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 4
- 201000010881 cervical cancer Diseases 0.000 claims description 4
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 4
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 4
- 201000004101 esophageal cancer Diseases 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 208000005017 glioblastoma Diseases 0.000 claims description 4
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 4
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 4
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 4
- 201000010982 kidney cancer Diseases 0.000 claims description 4
- 201000000062 kidney sarcoma Diseases 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 230000019491 signal transduction Effects 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 201000002510 thyroid cancer Diseases 0.000 claims description 4
- 206010044412 transitional cell carcinoma Diseases 0.000 claims description 4
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 4
- 206010046766 uterine cancer Diseases 0.000 claims description 4
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 3
- 201000009030 Carcinoma Diseases 0.000 claims description 3
- 208000026350 Inborn Genetic disease Diseases 0.000 claims description 3
- 210000000013 bile duct Anatomy 0.000 claims description 3
- 230000001419 dependent effect Effects 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 2
- 229910052805 deuterium Inorganic materials 0.000 claims description 2
- 125000004431 deuterium atom Chemical group 0.000 claims description 2
- 150000003254 radicals Chemical class 0.000 claims description 2
- GBXQPDCOMJJCMJ-UHFFFAOYSA-M trimethyl-[6-(trimethylazaniumyl)hexyl]azanium;bromide Chemical compound [Br-].C[N+](C)(C)CCCCCC[N+](C)(C)C GBXQPDCOMJJCMJ-UHFFFAOYSA-M 0.000 claims description 2
- 101001053401 Arabidopsis thaliana Acid beta-fructofuranosidase 3, vacuolar Proteins 0.000 claims 1
- 101001053395 Arabidopsis thaliana Acid beta-fructofuranosidase 4, vacuolar Proteins 0.000 claims 1
- 208000016361 genetic disease Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 153
- 238000006243 chemical reaction Methods 0.000 description 98
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 75
- 238000003786 synthesis reaction Methods 0.000 description 74
- 230000015572 biosynthetic process Effects 0.000 description 73
- 230000002829 reductive effect Effects 0.000 description 60
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 59
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 57
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 47
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 43
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 41
- QZILSYOEHMXZBE-UHFFFAOYSA-N pyrido[2,3-d]pyrimidin-4-amine Chemical compound C1=CC=C2C(N)=NC=NC2=N1 QZILSYOEHMXZBE-UHFFFAOYSA-N 0.000 description 37
- 239000000243 solution Substances 0.000 description 37
- 238000010898 silica gel chromatography Methods 0.000 description 34
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 32
- 229910052757 nitrogen Inorganic materials 0.000 description 29
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 27
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- 239000003480 eluent Substances 0.000 description 24
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 22
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 21
- OYRRZWATULMEPF-UHFFFAOYSA-N pyrimidin-4-amine Chemical compound NC1=CC=NC=N1 OYRRZWATULMEPF-UHFFFAOYSA-N 0.000 description 21
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 20
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 20
- 239000012074 organic phase Substances 0.000 description 19
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 19
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 16
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 16
- 125000002619 bicyclic group Chemical group 0.000 description 16
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 15
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 15
- 239000002994 raw material Substances 0.000 description 15
- 239000007858 starting material Substances 0.000 description 15
- 238000004809 thin layer chromatography Methods 0.000 description 15
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 15
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 14
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 14
- 102000016914 ras Proteins Human genes 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 13
- 239000000706 filtrate Substances 0.000 description 13
- 101150040459 RAS gene Proteins 0.000 description 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 12
- 238000000034 method Methods 0.000 description 10
- 125000003367 polycyclic group Chemical group 0.000 description 10
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 10
- 125000002950 monocyclic group Chemical group 0.000 description 9
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 9
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 8
- 101150076031 RAS1 gene Proteins 0.000 description 8
- 239000012141 concentrate Substances 0.000 description 8
- 230000007935 neutral effect Effects 0.000 description 8
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 8
- 125000006413 ring segment Chemical group 0.000 description 8
- 239000000741 silica gel Substances 0.000 description 8
- 229910002027 silica gel Inorganic materials 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- OKDPHZKIZBDGEF-UHFFFAOYSA-N CC1=NC(N=C(C(Br)=C2)OC)=C2C(O)=N1 Chemical compound CC1=NC(N=C(C(Br)=C2)OC)=C2C(O)=N1 OKDPHZKIZBDGEF-UHFFFAOYSA-N 0.000 description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 7
- 229910052799 carbon Inorganic materials 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- 239000001301 oxygen Substances 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- FEJUGLKDZJDVFY-UHFFFAOYSA-N 9-borabicyclo[3.3.1]nonane Substances C1CCC2CCCC1B2 FEJUGLKDZJDVFY-UHFFFAOYSA-N 0.000 description 6
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- MABMFMWGVUMCRY-MRVPVSSYSA-N C[C@H](C(C=CC=C1C(F)F)=C1F)NC1=NC(C)=NC(N=C2OC)=C1C=C2Br Chemical compound C[C@H](C(C=CC=C1C(F)F)=C1F)NC1=NC(C)=NC(N=C2OC)=C1C=C2Br MABMFMWGVUMCRY-MRVPVSSYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 6
- 239000000460 chlorine Substances 0.000 description 6
- 230000008034 disappearance Effects 0.000 description 6
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 6
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 6
- 239000003208 petroleum Substances 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
- 125000004943 pyrimidin-6-yl group Chemical group N1=CN=CC=C1* 0.000 description 6
- 108010014186 ras Proteins Proteins 0.000 description 6
- 102200006538 rs121913530 Human genes 0.000 description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 5
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 5
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 5
- 206010064571 Gene mutation Diseases 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- UDJFFSGCRRMVFH-UHFFFAOYSA-N pyrido[2,3-d]pyrimidine Chemical compound N1=CN=CC2=CC=CN=C21 UDJFFSGCRRMVFH-UHFFFAOYSA-N 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 5
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 4
- TYJWPCZIKQVKTQ-MRVPVSSYSA-N 6-bromo-N-[(1R)-1-[3-(difluoromethyl)-2-fluorophenyl]ethyl]-2-methylpyrido[2,3-d]pyrimidin-4-amine Chemical compound C[C@H](C(C=CC=C1C(F)F)=C1F)NC1=NC(C)=NC(N=C2)=C1C=C2Br TYJWPCZIKQVKTQ-MRVPVSSYSA-N 0.000 description 4
- AMKGKYQBASDDJB-UHFFFAOYSA-N 9$l^{2}-borabicyclo[3.3.1]nonane Chemical compound C1CCC2CCCC1[B]2 AMKGKYQBASDDJB-UHFFFAOYSA-N 0.000 description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 4
- PKJHGOSVRSDITJ-LLVKDONJSA-N C[C@H](C1=CC=CC(C#N)=C1C)NC1=NC(C)=NC(N=C2OC)=C1C=C2Br Chemical compound C[C@H](C1=CC=CC(C#N)=C1C)NC1=NC(C)=NC(N=C2OC)=C1C=C2Br PKJHGOSVRSDITJ-LLVKDONJSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 4
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- LJRZIUJGRVJBKS-GFCCVEGCSA-N N-[(1R)-1-[3-(difluoromethyl)-2-fluorophenyl]ethyl]-2-methyl-6-(1,2,3,6-tetrahydropyridin-4-yl)pyrido[2,3-d]pyrimidin-4-amine Chemical compound C[C@H](C(C=CC=C1C(F)F)=C1F)NC1=NC(C)=NC(N=C2)=C1C=C2C1=CCNCC1 LJRZIUJGRVJBKS-GFCCVEGCSA-N 0.000 description 4
- 229910020008 S(O) Inorganic materials 0.000 description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 4
- 229910052794 bromium Inorganic materials 0.000 description 4
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 4
- 229910000024 caesium carbonate Inorganic materials 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- JHRWWRDRBPCWTF-OLQVQODUSA-N captafol Chemical compound C1C=CC[C@H]2C(=O)N(SC(Cl)(Cl)C(Cl)Cl)C(=O)[C@H]21 JHRWWRDRBPCWTF-OLQVQODUSA-N 0.000 description 4
- 238000006482 condensation reaction Methods 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- FDPIMTJIUBPUKL-UHFFFAOYSA-N pentan-3-one Chemical compound CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 4
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 4
- 238000010791 quenching Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- JMXKSZRRTHPKDL-UHFFFAOYSA-N titanium ethoxide Chemical compound [Ti+4].CC[O-].CC[O-].CC[O-].CC[O-] JMXKSZRRTHPKDL-UHFFFAOYSA-N 0.000 description 4
- ANVNEJQGAFBOPA-OAHLLOKOSA-N 2-[4-[4-[[(1R)-1-[3-(difluoromethyl)-2-fluorophenyl]ethyl]amino]-2-methylpyrido[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl]-N,N-dimethylacetamide Chemical compound C[C@H](C(C=CC=C1C(F)F)=C1F)NC1=NC(C)=NC(N=C2)=C1C=C2C1=CCN(CC(N(C)C)=O)CC1 ANVNEJQGAFBOPA-OAHLLOKOSA-N 0.000 description 3
- UMKDPZGKJZQZAY-OGFXRTJISA-N 3-[(1r)-1-aminoethyl]benzonitrile;hydrochloride Chemical compound Cl.C[C@@H](N)C1=CC=CC(C#N)=C1 UMKDPZGKJZQZAY-OGFXRTJISA-N 0.000 description 3
- XUFFFYNXLJKFHN-UHFFFAOYSA-N 6-bromo-2-methyl-3H-pyrido[2,3-d]pyrimidin-4-one Chemical compound Cc1nc(=O)c2cc(Br)cnc2[nH]1 XUFFFYNXLJKFHN-UHFFFAOYSA-N 0.000 description 3
- QVMPPKGAPYNGIV-CYBMUJFWSA-N 7-methoxy-2-methyl-6-(4-methylpiperazin-1-yl)-N-[(1R)-1-[3-nitro-5-(trifluoromethyl)phenyl]ethyl]pyrido[2,3-d]pyrimidin-4-amine Chemical compound C[C@H](C1=CC([N+]([O-])=O)=CC(C(F)(F)F)=C1)NC1=NC(C)=NC(N=C2OC)=C1C=C2N1CCN(C)CC1 QVMPPKGAPYNGIV-CYBMUJFWSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 3
- BIPQTKYPISJPTP-UHFFFAOYSA-N COC(C(C=C1Br)=C(N)N=C1OC)=O Chemical compound COC(C(C=C1Br)=C(N)N=C1OC)=O BIPQTKYPISJPTP-UHFFFAOYSA-N 0.000 description 3
- 102100030708 GTPase KRas Human genes 0.000 description 3
- 102000018898 GTPase-Activating Proteins Human genes 0.000 description 3
- 108091006094 GTPase-accelerating proteins Proteins 0.000 description 3
- 102000016285 Guanine Nucleotide Exchange Factors Human genes 0.000 description 3
- 108010067218 Guanine Nucleotide Exchange Factors Proteins 0.000 description 3
- 239000007821 HATU Substances 0.000 description 3
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 3
- QYHBLLKWZREJCJ-GFCCVEGCSA-N N-[(1R)-1-[3-(difluoromethyl)-2-fluorophenyl]ethyl]-6-(3,6-dihydro-2H-pyran-4-yl)-7-methoxy-2-methylpyrido[2,3-d]pyrimidin-4-amine Chemical compound C[C@H](C(C=CC=C1C(F)F)=C1F)NC1=NC(C)=NC2=C1C=C(C1=CCOCC1)C(OC)=N2 QYHBLLKWZREJCJ-GFCCVEGCSA-N 0.000 description 3
- HQQQFIDZRYDTKJ-GFCCVEGCSA-N N-[(1R)-1-[3-(difluoromethyl)-2-fluorophenyl]ethyl]-7-methoxy-2-methyl-6-(oxan-4-yl)pyrido[2,3-d]pyrimidin-4-amine Chemical compound C[C@H](C(C=CC=C1C(F)F)=C1F)NC1=NC(C)=NC2=C1C=C(C1CCOCC1)C(OC)=N2 HQQQFIDZRYDTKJ-GFCCVEGCSA-N 0.000 description 3
- 101710115132 Son of sevenless homolog Proteins 0.000 description 3
- YATXEDQNQZCNJD-DDWIOCJRSA-N [(1R)-1-(3-cyano-2-methylphenyl)ethyl]azanium chloride Chemical compound C[C@H](C1=C(C)C(C#N)=CC=C1)N.Cl YATXEDQNQZCNJD-DDWIOCJRSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- XKXHCNPAFAXVRZ-UHFFFAOYSA-N benzylazanium;chloride Chemical compound [Cl-].[NH3+]CC1=CC=CC=C1 XKXHCNPAFAXVRZ-UHFFFAOYSA-N 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 238000006555 catalytic reaction Methods 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 238000006880 cross-coupling reaction Methods 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000012065 filter cake Substances 0.000 description 3
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- XAGCSAAIAXOBHQ-OAHLLOKOSA-N tert-butyl 4-[4-[[(1R)-1-[3-(difluoromethyl)-2-fluorophenyl]ethyl]amino]-2-methylpyrido[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylate Chemical compound C[C@H](C(C=CC=C1C(F)F)=C1F)NC1=NC(C)=NC(N=C2)=C1C=C2C(CC1)=CCN1C(OC(C)(C)C)=O XAGCSAAIAXOBHQ-OAHLLOKOSA-N 0.000 description 3
- CCTWENUXVOICEX-LLVKDONJSA-N tert-butyl N-[(1R)-1-(3-cyano-2-methylphenyl)ethyl]carbamate Chemical compound C(#N)C=1C(=C(C=CC=1)[C@@H](C)NC(OC(C)(C)C)=O)C CCTWENUXVOICEX-LLVKDONJSA-N 0.000 description 3
- 239000012224 working solution Substances 0.000 description 3
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 2
- CSXSSFFXBOCGBM-CYBMUJFWSA-N 1-[4-[4-[[(1R)-1-[3-(difluoromethyl)-2-fluorophenyl]ethyl]amino]-7-methoxy-2-methylpyrido[2,3-d]pyrimidin-6-yl]piperazin-1-yl]ethanone Chemical compound C[C@H](C(C=CC=C1C(F)F)=C1F)NC1=NC(C)=NC(N=C2OC)=C1C=C2N(CC1)CCN1C(C)=O CSXSSFFXBOCGBM-CYBMUJFWSA-N 0.000 description 2
- WKJRIJUCGJPRRD-UHFFFAOYSA-N 2-methylpyrido[2,3-d]pyrimidin-4-amine Chemical compound C1=CC=NC2=NC(C)=NC(N)=C21 WKJRIJUCGJPRRD-UHFFFAOYSA-N 0.000 description 2
- JSOUTHDHGSTUMU-CQSZACIVSA-N 3-[4-[4-[[(1R)-1-[3-(difluoromethyl)-2-fluorophenyl]ethyl]amino]-2-methylpyrido[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridin-1-yl]-3-oxopropanenitrile Chemical compound C[C@H](C(C=CC=C1C(F)F)=C1F)NC1=NC(C)=NC(N=C2)=C1C=C2C(CC1)=CCN1C(CC#N)=O JSOUTHDHGSTUMU-CQSZACIVSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- 208000028782 Hereditary disease Diseases 0.000 description 2
- 101150105104 Kras gene Proteins 0.000 description 2
- 208000024556 Mendelian disease Diseases 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- WKAIDVIKTVVLJQ-CQSZACIVSA-N N-[(1R)-1-[3-(difluoromethyl)-2-fluorophenyl]ethyl]-2-methyl-6-(2-morpholin-4-ylethoxy)pyrido[2,3-d]pyrimidin-4-amine Chemical compound C[C@H](C(C=CC=C1C(F)F)=C1F)NC1=NC(C)=NC(N=C2)=C1C=C2OCCN1CCOCC1 WKAIDVIKTVVLJQ-CQSZACIVSA-N 0.000 description 2
- OIISDJRWZAAPQI-GFCCVEGCSA-N N-[(1R)-1-[3-amino-5-(trifluoromethyl)phenyl]ethyl]-6-(3,6-dihydro-2H-pyran-4-yl)-7-methoxy-2-methylpyrido[2,3-d]pyrimidin-4-amine Chemical compound C[C@H](C1=CC(N)=CC(C(F)(F)F)=C1)NC1=NC(C)=NC2=C1C=C(C1=CCOCC1)C(OC)=N2 OIISDJRWZAAPQI-GFCCVEGCSA-N 0.000 description 2
- UEZQJECPFQNROV-CYBMUJFWSA-N N-[(1R)-1-[3-amino-5-(trifluoromethyl)phenyl]ethyl]-7-methoxy-2-methyl-6-(4-methylpiperazin-1-yl)pyrido[2,3-d]pyrimidin-4-amine Chemical compound C[C@H](C1=CC(N)=CC(C(F)(F)F)=C1)NC1=NC(C)=NC(N=C2OC)=C1C=C2N1CCN(C)CC1 UEZQJECPFQNROV-CYBMUJFWSA-N 0.000 description 2
- GTKHMHTWOBOGFT-QGZVFWFLSA-N N-[(1R)-1-[3-amino-5-(trifluoromethyl)phenyl]ethyl]-7-methoxy-2-methyl-6-(9-methyl-3,9-diazaspiro[5.5]undecan-3-yl)pyrido[2,3-d]pyrimidin-4-amine Chemical compound C[C@H](C1=CC(N)=CC(C(F)(F)F)=C1)NC1=NC(C)=NC(N=C2OC)=C1C=C2N1CCC2(CCN(C)CC2)CC1 GTKHMHTWOBOGFT-QGZVFWFLSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 230000003281 allosteric effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- MLIREBYILWEBDM-UHFFFAOYSA-N cyanoacetic acid Chemical compound OC(=O)CC#N MLIREBYILWEBDM-UHFFFAOYSA-N 0.000 description 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 2
- LMYJGUNNJIDROI-UHFFFAOYSA-N oxan-4-ol Chemical compound OC1CCOCC1 LMYJGUNNJIDROI-UHFFFAOYSA-N 0.000 description 2
- MUJIDPITZJWBSW-UHFFFAOYSA-N palladium(2+) Chemical compound [Pd+2] MUJIDPITZJWBSW-UHFFFAOYSA-N 0.000 description 2
- IVDFJHOHABJVEH-UHFFFAOYSA-N pinacol Chemical compound CC(C)(O)C(C)(C)O IVDFJHOHABJVEH-UHFFFAOYSA-N 0.000 description 2
- 235000011056 potassium acetate Nutrition 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000006824 pyrimidine synthesis Effects 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 108700042226 ras Genes Proteins 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- XKOOYFHELMABPJ-SNVBAGLBSA-N tert-butyl n-[(1r)-1-(3-bromo-2-methylphenyl)ethyl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@H](C)C1=CC=CC(Br)=C1C XKOOYFHELMABPJ-SNVBAGLBSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- RZBQSBXQOWBINI-RXMQYKEDSA-N (1R)-1-[3-nitro-5-(trifluoromethyl)phenyl]ethanamine Chemical compound C[C@@H](N)c1cc(cc(c1)C(F)(F)F)[N+]([O-])=O RZBQSBXQOWBINI-RXMQYKEDSA-N 0.000 description 1
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 1
- RCVDPBFUMYUKPB-UHFFFAOYSA-N (3,4-dimethoxyphenyl)boronic acid Chemical compound COC1=CC=C(B(O)O)C=C1OC RCVDPBFUMYUKPB-UHFFFAOYSA-N 0.000 description 1
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- 125000005988 1,1-dioxo-thiomorpholinyl group Chemical group 0.000 description 1
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 description 1
- 125000005918 1,2-dimethylbutyl group Chemical group 0.000 description 1
- LBNWYNIGDUWAOQ-UHFFFAOYSA-N 1-(3-bromo-2-methylphenyl)ethanone Chemical compound CC(=O)C1=CC=CC(Br)=C1C LBNWYNIGDUWAOQ-UHFFFAOYSA-N 0.000 description 1
- HUUPVABNAQUEJW-UHFFFAOYSA-N 1-methylpiperidin-4-one Chemical compound CN1CCC(=O)CC1 HUUPVABNAQUEJW-UHFFFAOYSA-N 0.000 description 1
- DNCYBUMDUBHIJZ-UHFFFAOYSA-N 1h-pyrimidin-6-one Chemical compound O=C1C=CN=CN1 DNCYBUMDUBHIJZ-UHFFFAOYSA-N 0.000 description 1
- HGUFODBRKLSHSI-UHFFFAOYSA-N 2,3,7,8-tetrachloro-dibenzo-p-dioxin Chemical compound O1C2=CC(Cl)=C(Cl)C=C2OC2=C1C=C(Cl)C(Cl)=C2 HGUFODBRKLSHSI-UHFFFAOYSA-N 0.000 description 1
- IEPDTLRHISNBLB-UHFFFAOYSA-N 2-amino-5-bromopyridine-3-carboxylic acid Chemical compound NC1=NC=C(Br)C=C1C(O)=O IEPDTLRHISNBLB-UHFFFAOYSA-N 0.000 description 1
- QPIOVNJLOVNTMW-UHFFFAOYSA-N 2-bromo-n,n-dimethylacetamide Chemical compound CN(C)C(=O)CBr QPIOVNJLOVNTMW-UHFFFAOYSA-N 0.000 description 1
- FZZMTSNZRBFGGU-UHFFFAOYSA-N 2-chloro-7-fluoroquinazolin-4-amine Chemical compound FC1=CC=C2C(N)=NC(Cl)=NC2=C1 FZZMTSNZRBFGGU-UHFFFAOYSA-N 0.000 description 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- BMIBJCFFZPYJHF-UHFFFAOYSA-N 2-methoxy-5-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine Chemical compound COC1=NC=C(C)C=C1B1OC(C)(C)C(C)(C)O1 BMIBJCFFZPYJHF-UHFFFAOYSA-N 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- 125000004637 2-oxopiperidinyl group Chemical group O=C1N(CCCC1)* 0.000 description 1
- CCONWWPPYYLDTF-OAHLLOKOSA-N 3-[(1R)-1-[(7-methoxy-2-methyl-6-morpholin-4-ylpyrido[2,3-d]pyrimidin-4-yl)amino]ethyl]-2-methylbenzonitrile Chemical compound C[C@H](C1=CC=CC(C#N)=C1C)NC1=NC(C)=NC(N=C2OC)=C1C=C2N1CCOCC1 CCONWWPPYYLDTF-OAHLLOKOSA-N 0.000 description 1
- QVWFWJQWWOZTAD-LJQANCHMSA-N 3-[(1R)-1-[[7-methoxy-2-methyl-6-(3-oxa-9-azaspiro[5.5]undecan-9-yl)pyrido[2,3-d]pyrimidin-4-yl]amino]ethyl]-2-methylbenzonitrile Chemical compound C[C@H](C1=CC=CC(C#N)=C1C)NC1=NC(C)=NC(N=C2OC)=C1C=C2N(CC1)CCC11CCOCC1 QVWFWJQWWOZTAD-LJQANCHMSA-N 0.000 description 1
- SBCFGFDAZCTSRH-UHFFFAOYSA-N 3-acetylbenzonitrile Chemical compound CC(=O)C1=CC=CC(C#N)=C1 SBCFGFDAZCTSRH-UHFFFAOYSA-N 0.000 description 1
- FSPCKFWOMKQBEH-UHFFFAOYSA-N 3-azaspiro[5.5]undecan-9-one;hydrochloride Chemical compound Cl.C1CC(=O)CCC11CCNCC1 FSPCKFWOMKQBEH-UHFFFAOYSA-N 0.000 description 1
- OFXQSNLQXDCJCP-UHFFFAOYSA-N 3-methyl-3,9-diazaspiro[5.5]undecane Chemical compound C1CN(C)CCC11CCNCC1 OFXQSNLQXDCJCP-UHFFFAOYSA-N 0.000 description 1
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- ZAPMTSHEXFEPSD-UHFFFAOYSA-N 4-(2-chloroethyl)morpholine Chemical compound ClCCN1CCOCC1 ZAPMTSHEXFEPSD-UHFFFAOYSA-N 0.000 description 1
- KCAJVHJQQBZUFA-GFCCVEGCSA-N 4-[4-[[(1R)-1-[3-(difluoromethyl)-2-fluorophenyl]ethyl]amino]-7-methoxy-2-methylpyrido[2,3-d]pyrimidin-6-yl]oxan-4-ol Chemical compound C[C@H](C(C=CC=C1C(F)F)=C1F)NC1=NC(C)=NC2=C1C=C(C1(CCOCC1)O)C(OC)=N2 KCAJVHJQQBZUFA-GFCCVEGCSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- RJJQFIQUVYWMKP-QGZVFWFLSA-N 7-methoxy-2-methyl-6-(9-methyl-3,9-diazaspiro[5.5]undecan-3-yl)-N-[(1R)-1-[3-nitro-5-(trifluoromethyl)phenyl]ethyl]pyrido[2,3-d]pyrimidin-4-amine Chemical compound C[C@H](C1=CC([N+]([O-])=O)=CC(C(F)(F)F)=C1)NC1=NC(C)=NC(N=C2OC)=C1C=C2N1CCC2(CCN(C)CC2)CC1 RJJQFIQUVYWMKP-QGZVFWFLSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 description 1
- XCIYLUBDPCGXSP-LLVKDONJSA-N CCOC(C1=CC(C(N[C@H](C)C2=CC([N+]([O-])=O)=CC(C(F)(F)F)=C2)=NC(C)=N2)=C2N=C1OC)=C Chemical compound CCOC(C1=CC(C(N[C@H](C)C2=CC([N+]([O-])=O)=CC(C(F)(F)F)=C2)=NC(C)=N2)=C2N=C1OC)=C XCIYLUBDPCGXSP-LLVKDONJSA-N 0.000 description 1
- SYALNGWMKYNPNH-MRVPVSSYSA-N C[C@H](C(C=CC=C1C(F)F)=C1F)NC1=NC(C)=NC(N=C2)=C1C=C2O Chemical compound C[C@H](C(C=CC=C1C(F)F)=C1F)NC1=NC(C)=NC(N=C2)=C1C=C2O SYALNGWMKYNPNH-MRVPVSSYSA-N 0.000 description 1
- RVNSNZPZZLQIPX-MRVPVSSYSA-N C[C@H](C1=CC([N+]([O-])=O)=CC(C(F)(F)F)=C1)NC1=NC(C)=NC(N=C2OC)=C1C=C2Br Chemical compound C[C@H](C1=CC([N+]([O-])=O)=CC(C(F)(F)F)=C1)NC1=NC(C)=NC(N=C2OC)=C1C=C2Br RVNSNZPZZLQIPX-MRVPVSSYSA-N 0.000 description 1
- VAVJBVQUWOGTNH-GFCCVEGCSA-N C[C@H](C1=CC([N+]([O-])=O)=CC(C(F)(F)F)=C1)NC1=NC(C)=NC(N=C2OC)=C1C=C2N1CCOCC1 Chemical compound C[C@H](C1=CC([N+]([O-])=O)=CC(C(F)(F)F)=C1)NC1=NC(C)=NC(N=C2OC)=C1C=C2N1CCOCC1 VAVJBVQUWOGTNH-GFCCVEGCSA-N 0.000 description 1
- TXSWJZSOGWYFCN-BZNIZROVSA-N C[C@H](C1=CC([N+]([O-])=O)=CC(C(F)(F)F)=C1)NC1=NC(C)=NC(N=C2OC)=C1C=C2O[C@@H]1COCC1 Chemical compound C[C@H](C1=CC([N+]([O-])=O)=CC(C(F)(F)F)=C1)NC1=NC(C)=NC(N=C2OC)=C1C=C2O[C@@H]1COCC1 TXSWJZSOGWYFCN-BZNIZROVSA-N 0.000 description 1
- BDWZLBGXMSVYMT-SECBINFHSA-N C[C@H](C1=CC([N+]([O-])=O)=CC(C(F)(F)F)=C1)NC1=NC(C)=NC2=C1C=C(C(C)=O)C(OC)=N2 Chemical compound C[C@H](C1=CC([N+]([O-])=O)=CC(C(F)(F)F)=C1)NC1=NC(C)=NC2=C1C=C(C(C)=O)C(OC)=N2 BDWZLBGXMSVYMT-SECBINFHSA-N 0.000 description 1
- TYVIZZSGIKQETE-CYBMUJFWSA-N C[C@H](C1=CC([N+]([O-])=O)=CC(C(F)(F)F)=C1)NC1=NC(C)=NC2=C1C=C(C(C=C1)=CC(OC)=C1OC)C(OC)=N2 Chemical compound C[C@H](C1=CC([N+]([O-])=O)=CC(C(F)(F)F)=C1)NC1=NC(C)=NC2=C1C=C(C(C=C1)=CC(OC)=C1OC)C(OC)=N2 TYVIZZSGIKQETE-CYBMUJFWSA-N 0.000 description 1
- BFJINHONHLAAPX-GFCCVEGCSA-N C[C@H](C1=CC([N+]([O-])=O)=CC(C(F)(F)F)=C1)NC1=NC(C)=NC2=C1C=C(C1=CCOCC1)C(OC)=N2 Chemical compound C[C@H](C1=CC([N+]([O-])=O)=CC(C(F)(F)F)=C1)NC1=NC(C)=NC2=C1C=C(C1=CCOCC1)C(OC)=N2 BFJINHONHLAAPX-GFCCVEGCSA-N 0.000 description 1
- ALJQBNRQNPFIEA-SNVBAGLBSA-N C[C@H](C1=CC=CC(C#N)=C1)NC1=NC(C)=NC(N=C2OC)=C1C=C2Br Chemical compound C[C@H](C1=CC=CC(C#N)=C1)NC1=NC(C)=NC(N=C2OC)=C1C=C2Br ALJQBNRQNPFIEA-SNVBAGLBSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- LMVWLMYIWIMIAX-NUBCRITNSA-N Cl.FC(C=1C(=C(C=CC=1)[C@@H](C)N)F)F Chemical compound Cl.FC(C=1C(=C(C=CC=1)[C@@H](C)N)F)F LMVWLMYIWIMIAX-NUBCRITNSA-N 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102000034286 G proteins Human genes 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000013446 GTP Phosphohydrolases Human genes 0.000 description 1
- 108091006109 GTPases Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229940124785 KRAS inhibitor Drugs 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- 101100193693 Kirsten murine sarcoma virus K-RAS gene Proteins 0.000 description 1
- 230000037364 MAPK/ERK pathway Effects 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- BTOJDIBUJZRGLY-GFCCVEGCSA-N N-[(1R)-1-[3-(difluoromethyl)-2-fluorophenyl]ethyl]-7-methoxy-2-methyl-6-pyrrolidin-1-ylpyrido[2,3-d]pyrimidin-4-amine Chemical compound C[C@H](C(C=CC=C1C(F)F)=C1F)NC1=NC(C)=NC(N=C2OC)=C1C=C2N1CCCC1 BTOJDIBUJZRGLY-GFCCVEGCSA-N 0.000 description 1
- ZTQQXQIOXBMXJW-CYBMUJFWSA-N N-[(1R)-1-[3-amino-5-(trifluoromethyl)phenyl]ethyl]-6-(3,4-dimethoxyphenyl)-7-methoxy-2-methylpyrido[2,3-d]pyrimidin-4-amine Chemical compound C[C@H](C1=CC(N)=CC(C(F)(F)F)=C1)NC1=NC(C)=NC2=C1C=C(C(C=C1)=CC(OC)=C1OC)C(OC)=N2 ZTQQXQIOXBMXJW-CYBMUJFWSA-N 0.000 description 1
- 101800000135 N-terminal protein Proteins 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 101800001452 P1 proteinase Proteins 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 229910002666 PdCl2 Inorganic materials 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 229940126271 SOS1 inhibitor Drugs 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical class [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 101150117474 Sos gene Proteins 0.000 description 1
- 238000006619 Stille reaction Methods 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- 241000255588 Tephritidae Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- WWCNXHYRAKUQDB-SNVBAGLBSA-N [(3r)-oxolan-3-yl] 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)O[C@H]1COCC1 WWCNXHYRAKUQDB-SNVBAGLBSA-N 0.000 description 1
- WJEIYVAPNMUNIU-UHFFFAOYSA-N [Na].OC(O)=O Chemical compound [Na].OC(O)=O WJEIYVAPNMUNIU-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- RROBIDXNTUAHFW-UHFFFAOYSA-N benzotriazol-1-yloxy-tris(dimethylamino)phosphanium Chemical compound C1=CC=C2N(O[P+](N(C)C)(N(C)C)N(C)C)N=NC2=C1 RROBIDXNTUAHFW-UHFFFAOYSA-N 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 150000001602 bicycloalkyls Chemical group 0.000 description 1
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 1
- 238000012925 biological evaluation Methods 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- WLVKDFJTYKELLQ-UHFFFAOYSA-N cyclopropylboronic acid Chemical compound OB(O)C1CC1 WLVKDFJTYKELLQ-UHFFFAOYSA-N 0.000 description 1
- 125000004855 decalinyl group Chemical group C1(CCCC2CCCCC12)* 0.000 description 1
- YNHIGQDRGKUECZ-UHFFFAOYSA-N dichloropalladium;triphenylphosphanium Chemical compound Cl[Pd]Cl.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-N 0.000 description 1
- MXFYYFVVIIWKFE-UHFFFAOYSA-N dicyclohexyl-[2-[2,6-di(propan-2-yloxy)phenyl]phenyl]phosphane Chemical group CC(C)OC1=CC=CC(OC(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 MXFYYFVVIIWKFE-UHFFFAOYSA-N 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 102000034238 globular proteins Human genes 0.000 description 1
- 108091005896 globular proteins Proteins 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 150000003949 imides Chemical class 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- IWCRNCDRJMTEMA-UHFFFAOYSA-N methyl 2-amino-6-methoxypyridine-3-carboxylate Chemical compound COC(=O)C1=CC=C(OC)N=C1N IWCRNCDRJMTEMA-UHFFFAOYSA-N 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 125000005476 oxopyrrolidinyl group Chemical group 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
- IWELDVXSEVIIGI-UHFFFAOYSA-N piperazin-2-one Chemical compound O=C1CNCCN1 IWELDVXSEVIIGI-UHFFFAOYSA-N 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical class [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- NXQKSXLFSAEQCZ-SFHVURJKSA-N sotorasib Chemical compound FC1=CC2=C(N(C(N=C2N2[C@H](CN(CC2)C(C=C)=O)C)=O)C=2C(=NC=CC=2C)C(C)C)N=C1C1=C(C=CC=C1O)F NXQKSXLFSAEQCZ-SFHVURJKSA-N 0.000 description 1
- VNFWTIYUKDMAOP-UHFFFAOYSA-N sphos Chemical group COC1=CC=CC(OC)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 VNFWTIYUKDMAOP-UHFFFAOYSA-N 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- VVDCRJGWILREQH-UHFFFAOYSA-N tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-2h-pyridine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCC(B2OC(C)(C)C(C)(C)O2)=C1 VVDCRJGWILREQH-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- PBIMIGNDTBRRPI-UHFFFAOYSA-N trifluoro borate Chemical compound FOB(OF)OF PBIMIGNDTBRRPI-UHFFFAOYSA-N 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- FJKIXWOMBXYWOQ-UHFFFAOYSA-N vinyl ethyl ether Natural products CCOC=C FJKIXWOMBXYWOQ-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Definitions
- the present invention relates to a substituted pyridopyrimidine derivative, its preparation method, a pharmaceutical composition containing the derivative, and its use as a therapeutic agent, especially as an SOS1 inhibitor.
- RAS genes are widely present in various eukaryotes such as mammals, fruit flies, fungi, nematodes and yeast, and have important physiological functions in various life systems.
- the mammalian RAS gene family has three members, namely H- RAS, K-RAS and N-RAS, various RAS genes have similar structures, all composed of four exons, distributed on the DNA of about 30kb in length.
- Their encoded products are monomeric globular proteins with a relative molecular mass of 21 kDa.
- the activation and inactivation states of RAS proteins have a significant impact on life processes such as cell growth, differentiation, proliferation and apoptosis.
- This protein is a membrane-bound guanine nucleotide-binding protein with weak GTPase activity, which regulates RAS through GTPase activating proteins (GAPs) and guanine nucleotide exchange factors (GEFs) in normal physiological activities
- GAPs GTPase activating proteins
- GEFs guanine nucleotide exchange factors
- RAS protein when combines with GTP to form RAS-GTP, it is in the active state.
- GTPase activating protein can dephosphorylate RAS-GTP into RAS-GDP, and then inactivate; the inactivated RAS-GDP is in guanine.
- nucleotide exchange factors Under the action of nucleotide exchange factors, it is converted into active RAS-GTP, thereby activating a series of downstream pathways such as RAF/MER/ERK and PI3K/AKT/mTOR.
- the RAS gene is also closely related to various human diseases, especially in cancer, RAS is an oncogene that frequently mutates, among which KRAS subtype gene mutations account for 86% of the total number of RAS gene mutations, about 90% of pancreatic cancer, Different degrees of KRAS gene mutation occur in 30%-40% of colon cancers and 15-20% of lung cancers. Given the prevalence of KRAS gene mutations, this target has always been the focus of drug development workers. Since the publication of the clinical results of AMG-510, which directly acts on the KRAS-G12C target, the research on KRAS inhibitors has set off a boom at home and abroad.
- the SOS (Son of sevenless homolog) protein was originally discovered in Drosophila studies and is a guanosine-releasing protein encoded by the SOS gene.
- Humans have two SOS homologues, hSOS1 and hSOS2, both of which are members of the guanine nucleotide exchange factor family with 70% homology. Although they are highly similar in structure and sequence, their physiological There are some differences in functionality.
- hSOS1 protein is 150kDa in size and is a multi-structural protein domain composed of 1333 amino acids, including N-terminal protein domain (HD), multiple homology domains, helical linker (HL), RAS exchange sequence (REM) and rich C-terminal domain of proline.
- HD N-terminal protein domain
- HL helical linker
- REM RAS exchange sequence
- hSOS1 There are two binding sites on hSOS1 with RAS protein, namely catalytic site and allosteric site.
- the catalytic site binds to the RAS protein on the RAS-GDP complex to promote guanine nucleotide exchange
- the allosteric site binds
- the RAS protein on the RAS-GTP complex further enhances the catalytic effect, and then participates in and activates the signal transduction of RAS family proteins.
- Studies have shown that inhibition of SOS1 not only completely inhibited the RAS-RAF-MEK-ERK pathway in wild-type KRAS cells, but also resulted in a 50% reduction in phospho-ERK activity in mutant KRAS cell lines.
- inhibition of SOS1 can also reduce the activity of RAS, thereby treating various cancers caused by RAS gene mutation or RAS protein overactivation, including pancreatic cancer, lung cancer, colorectal cancer, cholangiocarcinoma, multiple myeloma, melanoma tumor, uterine cancer, endometrial cancer, thyroid cancer, acute myeloid leukemia, bladder cancer, urothelial cancer, gastric cancer, cervical cancer, head and neck squamous cell carcinoma, diffuse large B-cell lymphoma, esophageal cancer , chronic lymphocytic leukemia, hepatocellular carcinoma, breast cancer, ovarian cancer, prostate cancer, glioblastoma, kidney cancer and sarcoma, etc.
- pancreatic cancer lung cancer, colorectal cancer, cholangiocarcinoma, multiple myeloma, melanoma tumor, uterine cancer, endometrial cancer, thyroid cancer, acute myeloid leukemia, bladder cancer,
- the present invention provides a substituted pyridopyrimidine compound of general formula (I) or a stereoisomer, tautomer or a pharmaceutically acceptable salt thereof:
- Ring A is selected from C 6 -C 10 aryl, 5-10 membered heteroaryl, 9-10 membered bicyclic heterocyclyl, 9-10 membered bicyclic aryl or 9-10 membered fused ring;
- R 2 is selected from halogen, cyano, C 1 -C 6 alkyl, C 3 -C 10 cycloalkyl, 4-11 membered heterocyclyl, C 6 -C 10 aryl, 5-10 membered heteroaryl, -OR 4 , -C(O)R 5 , -NR 6 C(O)R 7 , -CH 2 NR 8 R 9 , -C(O)NR 8 R 9 , or -NR 8 R 9 ; wherein, the alkyl, cycloalkyl, heterocyclic, aryl or heteroaryl is optionally further substituted by one or more substituents selected from R 10 ;
- R 3 is selected from hydrogen atom, C 1 -C 6 alkyl, C 1 -C 3 alkoxy, C 3 -C 10 cycloalkyl, 5-10 membered heteroaryl or -C(O)R 5 ; wherein , the alkyl group, alkoxy group, cycloalkyl group, heterocyclic group, aryl group or heteroaryl group are optionally further substituted by one or more substituents selected from R 10 ;
- R 5 is each independently selected from C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, 4-11 membered heterocyclyl, -NR 8 R 9 ; wherein said alkyl, cycloalkyl or heterocyclyl
- the cyclic group is optionally further substituted with one or more substituents selected from hydroxy, halogen, cyano, amino, C 1 -C 6 alkoxy;
- R 6 is selected from hydrogen, C 1 -C 3 alkyl or C 3 -C 6 cycloalkyl
- R 11 is selected from C 1 -C 6 alkyl or C 3 -C 6 cycloalkyl; wherein said alkyl or cycloalkyl is optionally further selected from one or more halogen, cyano, hydroxyl, C 1 -C 3 alkoxy, -N(CH 3 ) 2 , -N(C 2 H 5 ) 2 or 4-11-membered heterocyclic group substituents; the 4-11-membered heterocyclic group is optional is further substituted by C 1 -C 3 alkyl or C 1 -C 3 alkoxy;
- R 12 and R 13 are each independently selected from hydrogen, C 1 -C 3 alkyl or C 3 -C 6 cycloalkyl;
- R 14 is selected from halogen, hydroxy, cyano, amino, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 hydroxyalkyl or -C(O)R 15 ; wherein said The alkyl, alkoxy or hydroxyalkyl groups are optionally further substituted by one or more selected from halogen, C 1 -C 3 alkoxy, -N(CH 3 ) 2 , -N(C 2 H 5 ) 2 ,
- R 15 is selected from C 1 -C 6 alkyl or C 3 -C 6 cycloalkyl; wherein said alkyl or cycloalkyl is optionally further selected by one or more selected from halogen, hydroxyl, cyano, C 1 - C 3 alkoxy, -N(CH 3 ) 2 , -N(C 2 H 5 ) 2 or substituents of 4-11-membered heterocyclic groups;
- n 1, 2 or 3.
- a preferred embodiment of the present invention is a compound represented by the general formula (I) or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof, which is the general formula (II-1), (II- 2)
- R 1 , R 2 , R 3 and m are defined as described in the general formula (I).
- a preferred embodiment of the present invention is a compound represented by general formula (I) or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, which is a compound represented by general formula (III) or its Stereoisomers, tautomers or pharmaceutically acceptable salts thereof:
- Ring B is selected from C 3 -C 10 cycloalkyl, 4-11 membered heterocyclyl, C 6 -C 10 aryl or 5-10 membered heteroaryl;
- n is selected from 0, 1, 2, 3 or 4;
- Rings A, R 1 , R 3 , R 10 and m are as defined in general formula (I).
- a preferred embodiment of the present invention is a compound represented by the general formula (I) or a stereoisomer, tautomer or a pharmaceutically acceptable salt thereof, which is the general formula (IV-1), (IV- 2)
- ring A, R 1 , R 3 , R 6 , R 7 , R 8 , R 9 and m are as defined in general formula (I).
- a preferred embodiment of the present invention is a compound represented by general formula (I) or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, which is a compound represented by general formula (V) or its Stereoisomers, tautomers or pharmaceutically acceptable salts thereof:
- ring A, R 1 , R 3 , R 4 and m are as defined in general formula (I).
- a preferred embodiment of the present invention is a compound represented by the general formula (I) or a stereoisomer, tautomer or a pharmaceutically acceptable salt thereof, which is the general formula (VI-1), (VI- 2), the compound shown in (VI-3) or (VI-4) or its stereoisomer, tautomer or its pharmaceutically acceptable salt:
- Rings A, R 1 , R 3 , R 8 , R 9 and m are as defined in general formula (I).
- a preferred version of the present invention is a compound represented by general formula (III) or a stereoisomer, tautomer or a pharmaceutically acceptable salt thereof, wherein:
- R 10 and n are as defined in general formula (III).
- the compound of general formula (I) is selected from:
- the present invention provides a pharmaceutical composition containing effective doses of general formula (I), (II-1), (II-2), (II-3), (III), The compound described in (IV-1), (IV-2), (V), (VI-1), (VI-2), (VI-3) or (VI-4) or a stereoisomer thereof, Tautomers or pharmaceutically acceptable salts thereof, and pharmaceutically acceptable carriers, excipients or combinations thereof.
- the present invention provides a kind of general formula (I), (II-1), (II-2), (II-3), (III), (IV-1), (IV-2), (V), ( The compound described in VI-1), (VI-2), (VI-3) or (VI-4) or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof, or a pharmaceutical combination thereof Use of compounds in the preparation of SOS1 inhibitors.
- the present invention also provides a general formula (I), (II-1), (II-2), (II-3), (III), (IV-1), (IV-2), (V),
- the compound described in (VI-1), (VI-2), (VI-3) or (VI-4) or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof, or a drug thereof Use of the composition in the preparation of a medicament for the treatment of diseases mediated by SOS1, wherein the diseases mediated by SOS1 are preferably RAS family protein signaling pathway-dependent related cancers, cancers caused by SOS1 mutations or caused by SOS1 mutations
- the hereditary disease; wherein said disease mediated by SOS1 is preferably pancreatic cancer, lung cancer, colorectal cancer, bile duct epithelial cancer, multiple myeloma, melanoma, uterine cancer, endometrial cancer, thyroid cancer, acute Myeloid leukemia, bladder cancer, urothelial cancer, gastric cancer, cervical
- the present invention further provides a general formula (I), (II-1), (II-2), (II-3), (III), (IV-1), (IV-2), (V),
- the compound described in (VI-1), (VI-2), (VI-3) or (VI-4) or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof, or a drug thereof Use of the composition in the preparation of a medicament for treating RAS family protein signal transduction pathway-dependent related cancer, cancer caused by SOS1 mutation or hereditary disease caused by SOS1 mutation.
- the present invention provides a kind of general formula (I), (II-1), (II-2), (II-3), (III), (IV-1), (IV-2), (V), ( The compound described in VI-1), (VI-2), (VI-3) or (VI-4) or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof, or a pharmaceutical combination thereof
- lung cancer colorectal cancer, bile duct epithelial cancer, multiple myeloma, melanoma, uterine cancer, endometrial cancer, thyroid cancer, acute myeloid leukemia, bladder cancer, urothelial cancer, gastric cancer , cervical cancer, head and neck squamous cell carcinoma, diffuse large B-cell lymphoma, esophageal cancer, chronic lymphocytic leukemia, hepatocellular carcinoma, breast cancer, ovarian cancer, prostate cancer, glioblastoma, kidney cancer and sarcoma drugs.
- Alkyl when taken as a group or part of a group is meant to include C1 - C20 straight or branched chain aliphatic hydrocarbon groups. Preferably it is a C 1 -C 10 alkyl group, more preferably a C 1 -C 6 alkyl group.
- alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-di Methylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1 -Ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethyl Butyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl Wait. Alkyl groups can be substituted or unsubstituted.
- Cycloalkyl refers to saturated or partially saturated monocyclic, fused, bridged and spirocyclic carbocyclic rings. Preferably it is C 3 -C 12 cycloalkyl, more preferably C 3 -C 8 cycloalkyl, most preferably C 3 -C 6 cycloalkyl.
- Examples of monocyclic cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptyl Alkenyl, cyclooctyl, etc., preferably cyclopropyl and cyclohexenyl. Cycloalkyl groups can be substituted or unsubstituted.
- “Spirocycloalkyl” refers to a polycyclic group with 5 to 18 members, two or more cyclic structures, and a single carbon atom (called a spiro atom) is shared between the monocyclic rings, and the ring may contain one or more Aromatic systems with multiple double bonds, but none of the rings have fully conjugated pi electrons. Preferably it is 6 to 14 yuan, more preferably 7 to 10 yuan.
- spirocycloalkyl groups are divided into mono-spiro, double-spiro or poly-spirocycloalkyl groups, preferably mono-spiro and double-spirocycloalkyl groups, preferably 4-membered/5-membered, 4-membered Yuan/6 Yuan, 5 Yuan/5 Yuan or 5 Yuan/6 Yuan.
- spirocycloalkyl include, but are not limited to, spiro[4.5]decyl, spiro[4.4]nonyl, spiro[3.5]nonyl, spiro[2.4]heptyl.
- “Fused cycloalkyl” refers to a 5- to 18-membered all-carbon polycyclic group containing two or more cyclic structures sharing a pair of carbon atoms with each other, one or more rings may contain one or more double bonds, But none of the rings have an aromatic system with fully conjugated pi electrons, preferably 6 to 12 membered, more preferably 7 to 10 membered. According to the number of formed rings, it can be divided into bicyclic, tricyclic, tetracyclic or polycyclic fused cycloalkyl, preferably bicyclic or tricyclic, more preferably 5-membered/5-membered or 5-membered/6-membered bicycloalkyl.
- fused cycloalkyl include, but are not limited to: bicyclo[3.1.0]hexyl, bicyclo[3.2.0]hept-1-enyl, bicyclo[3.2.0]heptyl, Decalinyl or tetrahydrophenanthryl.
- “Bridged cycloalkyl” refers to an all-carbon polycyclic group of 5 to 18 members, containing two or more cyclic structures, sharing two carbon atoms that are not directly connected to each other, and one or more rings may contain one or more Aromatic systems in which multiple double bonds, but none of the rings have fully conjugated pi electrons, are preferably 6 to 12 membered, more preferably 7 to 10 membered. According to the number of constituent rings, it can be divided into bicyclic, tricyclic, tetracyclic or polycyclic bridged cycloalkyl, preferably bicyclic, tricyclic or tetracyclic, more preferably bicyclic or tricyclic.
- bridged cycloalkyl include, but are not limited to: (1s,4s)-bicyclo[2.2.1]heptyl, bicyclo[3.2.1]octyl, (1s,5s)-dicyclo[3.2.1]octyl Cyclo[3.3.1]nonyl, bicyclo[2.2.2]octyl, (1r,5r)-bicyclo[3.3.2]decyl.
- Heterocyclyl “heterocycle,” or “heterocyclic” are used interchangeably herein to refer to a non-aromatic heterocyclyl in which one or more of the ring-forming atoms is a heteroatom, such as oxygen, Nitrogen, sulfur atoms, etc., including monocyclic, polycyclic, fused, bridged and spirocyclic. It preferably has a 5 to 7 membered monocyclic or 7 to 10 membered bicyclic or tricyclic ring, which may contain 1, 2 or 3 atoms selected from nitrogen, oxygen and/or sulphur.
- Examples of “monocyclic heterocyclyl” include, but are not limited to, morpholinyl, oxetanyl, thiomorpholinyl, tetrahydrofuranyl, tetrahydropyranyl, 1,1-dioxo-thiomorpho Linyl, piperidinyl, 2-oxo-piperidinyl, pyrrolidinyl, 2-oxo-pyrrolidinyl, piperazin-2-one, piperazinyl, hexahydropyrimidinyl,
- Monocyclic heterocyclyl groups may be substituted or unsubstituted.
- “Spiroheterocyclyl” refers to a 5- to 18-membered polycyclic group with two or more cyclic structures, and the single rings share one atom with each other, and the ring may contain one or more double bonds, but Aromatic systems in which none of the rings has fully conjugated pi electrons, wherein one or more ring atoms are selected from nitrogen, oxygen, or heteroatoms of S(O) n (wherein n is selected from 0, 1, or 2), and the remaining ring atoms for carbon. Preferably it is 6 to 14 yuan, more preferably 7 to 10 yuan.
- Spirocycloalkyl groups are classified into mono-spiroheterocyclyl, bis-spiroheterocyclyl or poly-spiroheterocyclyl according to the number of spiro atoms shared between rings, preferably mono-spiroheterocyclyl and bis-spiroheterocyclyl. More preferably, it is a 4-membered/4-membered, 4-membered/5-membered, 4-membered/6-membered, 5-membered/5-membered or 5-membered/6-membered monospiroheterocyclyl group.
- spiroheterocyclyl include, but are not limited to: 1,7-dioxaspiro[4.5]decyl, 2-oxa-7-azaspiro[4.4]nonyl, 7-oxaspiro[4.4]nonyl Heterospiro[3.5]nonyl, 5-oxaspiro[2.4]heptyl,
- Spiroheterocyclyl can be substituted or unsubstituted.
- Fused heterocyclyl refers to a polycyclic group containing two or more ring structures that share a pair of atoms with each other, one or more rings may contain one or more double bonds, but none of the rings is fully conjugated
- a pi-electron aromatic system in which one or more ring atoms are selected from nitrogen, oxygen or a heteroatom of S(O) n (wherein n is selected from 0, 1 or 2) and the remaining ring atoms are carbon.
- n is selected from 0, 1 or 2
- it is 6 to 14 yuan, more preferably 7 to 10 yuan.
- bicyclic, tricyclic, tetracyclic or polycyclic fused heterocyclic groups preferably bicyclic or tricyclic, more preferably 5-membered/5-membered or 5-membered/6-membered bicyclic fused heterocyclic groups.
- fused heterocyclyl include, but are not limited to: octahydropyrrolo[3,4-c]pyrrolyl, octahydro-1H-isoindolyl, 3-azabicyclo[3.1. 0] Hexyl, octahydrobenzo[b][1,4]dioxine.
- “Bridged heterocyclyl” refers to a 5- to 14-membered, 5- to 18-membered polycyclic group containing two or more cyclic structures that share two atoms that are not directly connected to each other, and one or more rings may be Aromatic systems containing one or more double bonds but none of the rings have fully conjugated pi electrons, wherein one or more ring atoms are selected from nitrogen, oxygen or S(O) n (wherein n is selected from 0, 1 or 2), the remaining ring atoms are carbon. Preferably it is 6 to 14 yuan, more preferably 7 to 10 yuan.
- bridged heterocyclyl include, but are not limited to: 2-azabicyclo[2.2.1]heptyl, 2-azabicyclo[2.2.2]octyl, 2-azabicyclo cyclo[3.3.2]decyl,
- Bridged heterocyclyl groups can be substituted or unsubstituted.
- Aryl refers to a carbocyclic aromatic system containing one or two rings, wherein the rings may be joined together in a fused fashion.
- aryl includes monocyclic or bicyclic aryl groups such as phenyl, naphthyl, tetrahydronaphthyl aromatic groups. Preferred aryl groups are C6 - C10 aryl groups, more preferred aryl groups are phenyl and naphthyl, and most preferred are phenyl groups.
- Aryl groups can be substituted or unsubstituted.
- Heteroaryl refers to an aromatic 5 to 6 membered monocyclic or 8 to 10 membered bicyclic ring, which may contain 1 to 4 atoms selected from nitrogen, oxygen and/or sulfur.
- heteroaryl include, but are not limited to, furyl, pyridyl, 2-oxo-1,2-dihydropyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, thienyl, isoxazolyl , oxazolyl, oxadiazolyl, imidazolyl, pyrrolyl, pyrazolyl, triazolyl, tetrazolyl, thiazolyl, isothiazolyl, 1,2,3-thiadiazolyl, benzom- Dioxolyl, benzothienyl, benzimidazolyl, indolyl, isoindolyl, 1,3-dioxo-isoin
- Heteroaryl groups can be substituted or unsubstituted.
- “Fused ring” refers to a polycyclic group in which two or more ring structures share a pair of atoms with each other, one or more rings may contain one or more double bonds, but at least one ring is not completely conjugated A pi-electron aromatic system, wherein the ring atoms are selected from 0, one or more heteroatoms selected from nitrogen, oxygen or S(O) r (wherein r is selected from 0, 1 or 2), and the remaining ring atoms are carbon .
- the condensed ring preferably includes a bicyclic or tricyclic condensed ring, wherein the bicyclic condensed ring is preferably a condensed ring of an aryl group or a heteroaryl group and a monocyclic heterocyclic group or a monocyclic cycloalkyl group. Preferably it is 7 to 14 yuan, more preferably 8 to 10 yuan. Examples of "fused rings" include, but are not limited to:
- Alkoxy refers to a group (alkyl-O-). Wherein, alkyl is as defined herein. Ci - C6 alkoxy groups are preferred. Examples include, but are not limited to: methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, tert-butoxy, and the like.
- C 1 -C 6 hydroxyalkyl refers to a hydroxy substituted C 1 -C 6 alkyl group.
- C 1 -C 6 haloalkyl refers to a halogen substituted C 1 -C 6 alkyl group.
- Halogen refers to fluorine, chlorine, bromine and iodine.
- Amino refers to -NH2 .
- Cyano refers to -CN.
- Niro refers to -NO2 .
- Benzyl refers to -CH2 -phenyl.
- DMSO dimethyl sulfoxide
- DMF N,N-dimethylformamide
- BOP refers to benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate.
- DBU refers to 1,8-diazabicyclo[5.4.0]undec-7-ene.
- DCC refers to dicyclohexylcarbodiimide.
- EDCI refers to 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide.
- PdCl2 (dppf) refers to [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride.
- Pd( PPh3 ) 2Cl2 refers to bis(triphenylphosphine)palladium dichloride .
- Pd2(dba )3 refers to tris(dibenzylideneacetone)dipalladium.
- XantPhos refers to 4,5-bisdiphenylphosphino-9,9-dimethylxanthene.
- HATU refers to 2-(7-azabenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate.
- 9-BBN refers to 9-borabicyclo[3.3.1]nonane.
- SPhos-Pd-G3 refers to methanesulfonic acid (2-dicyclohexylphosphino-2',6'-dimethoxy-1,1'-biphenyl)(2'-amino-1,1' - Biphenyl-2-yl)palladium(II).
- leaving group is an atom or functional group that is removed from a larger molecule in a chemical reaction, and is a term used in nucleophilic substitution and elimination reactions.
- the reactant attacked by the nucleophile is called the substrate, and the atom or group of atoms that is broken off with a pair of electrons from the substrate molecule is called the leaving group.
- Groups that readily accept electrons and have a strong ability to withstand negative charges are good leaving groups. When the pKa of the conjugated acid of the leaving group is smaller, the easier it is for the leaving group to detach from other molecules.
- Common leaving groups include, but are not limited to, halo, methanesulfonyl, -OTs, or -OH.
- Substituted means that one or more hydrogen atoms in a group, preferably up to 5, more preferably 1 to 3 hydrogen atoms, independently of one another, are substituted by the corresponding number of substituents. It goes without saying that the substituents are only in their possible chemical positions, and the person skilled in the art can determine (either experimentally or theoretically) possible or impossible substitutions without undue effort. For example, amino or hydroxyl groups with free hydrogens may be unstable when combined with carbon atoms with unsaturated (e.g., olefinic) bonds.
- “Pharmaceutically acceptable salts” refers to certain salts of the above-mentioned compounds that retain their original biological activity and are suitable for medicinal use.
- the pharmaceutically acceptable salt of the compound represented by the general formula (I) may be a metal salt or an amine salt formed with a suitable acid.
- “Pharmaceutical composition” means a mixture containing one or more of the compounds described herein, or a physiologically pharmaceutically acceptable salt or prodrug thereof, with other chemical components, and other components such as physiologically pharmaceutically acceptable carriers and excipients Form.
- the purpose of the pharmaceutical composition is to facilitate the administration to the organism, facilitate the absorption of the active ingredient and then exert the biological activity.
- the present invention provides a preparation method of a compound of general formula (I) or a stereoisomer, tautomer or a pharmaceutically acceptable salt thereof, the method comprising:
- the compound of general formula (IA) and compound (IB) undergo condensation reaction under the condition of a condensing agent, preferably BOP condensing agent, DCC condensing agent, EDCI condensing agent and HATU condensing agent, to obtain the compound of general formula (I); when R 1 When containing a nitro group, it can be further reduced to an amino group;
- a condensing agent preferably BOP condensing agent, DCC condensing agent, EDCI condensing agent and HATU condensing agent
- R 1 , R 2 , R 3 and m are as described in the general formula (I).
- the present invention provides a preparation method of compounds of general formula (II-1), (II-2), (II-3) or stereoisomers, tautomers or pharmaceutically acceptable salts thereof.
- the methods described include:
- the compound of general formula (IA) and the compound (IIB-2) are respectively subjected to a condensation reaction to obtain the general formula (II-2); the compound of (II-2) can be further rationally transformed;
- Described condensing agent is preferably BOP condensing agent, DCC condensing agent, EDCI condensing agent or HATU condensing agent;
- the rational transformation includes, when R 1 contains a nitro group, the nitro group can be further reduced to an amino group;
- R 1 , R 2 , R 3 and m are as described in the general formulae (II-1), (II-2), (II-3).
- the present invention provides a preparation method of a compound of general formula (III) or a stereoisomer, tautomer or a pharmaceutically acceptable salt thereof, the method comprising:
- X is selected from halogen, preferably bromine
- M is selected from H, -B(OH) 2 , -BF3K , -MgX or
- Ring B is selected from C 3 -C 10 cycloalkyl, 4-11 membered heterocyclyl, C 6 -C 10 aryl or 5-10 membered heteroaryl;
- Rings A, R 1 , R 3 , R 10 , m and n are as defined in general formula (III).
- the present invention provides a preparation method of a compound of general formula (IV-1), (IV-2) or its stereoisomer, tautomer or pharmaceutically acceptable salt thereof, said method comprising:
- the compound of general formula (IIIA) and compound (IVB-1) are subjected to a cross-coupling reaction under metal catalysis to obtain the compound of general formula (IV-1); the compound of (IV-1) can be further rationally transformed;
- compound (IV-2) are subjected to a cross-coupling reaction under metal catalysis to obtain compound (IV-2); compound (IV-2) can be further rationally transformed;
- X is selected from halogen, preferably bromine
- Ring A, R 1 , R 3 , R 6 , R 7 , R 8 , R 9 and m are as defined in general formulae (IV-1) and (IV-2).
- the present invention provides a preparation method of a compound of general formula (V) or a stereoisomer, tautomer or a pharmaceutically acceptable salt thereof, the method comprising:
- the compound of general formula (IIIA) and compound (VB) are subjected to a cross-coupling reaction under metal catalysis to obtain the compound of general formula (V); when R 1 contains a nitro group, it can be further reduced to an amino group.
- X is selected from halogen, preferably bromine
- Rings A, R 1 , R 3 , R 4 and m are as defined in general formula (V).
- the compound of general formula (IIIA) reacts with pinacol biboronate under metal catalysis to obtain the compound of general formula (VC); the compound of general formula (VC) is oxidized to obtain the compound of general formula (VD); the compound of general formula (VD) and The compound of general formula (VE) undergoes a nucleophilic substitution reaction to obtain the compound of general formula (V);
- X is selected from halogen, preferably bromine
- L is selected from leaving groups, preferably p-toluenesulfonate and halogen;
- Rings A, R 1 , R 3 , R 4 and m are as defined in general formula (V).
- the present invention provides a compound of general formula (VI-1), (VI-2), (VI-3), (VI-4) or a stereoisomer, tautomer or pharmaceutically acceptable compound thereof
- the preparation method of salt, described method comprises:
- the compound of general formula (IIIA) is subjected to carbonylation reaction under metal catalysis to obtain the compound of general formula (VIB-1); the compound of general formula (VIB-1) is hydrolyzed to generate carboxylic acid to obtain the compound of general formula (VIC); further react with HNR 8 R 9 undergoes a condensation reaction under the condition of a condensing agent to obtain a compound of general formula (VI-1);
- the compound of the general formula (IIIA) is subjected to a cross-coupling reaction under metal catalysis, and hydrolyzed to obtain the compound of the general formula (VIB-2); the compound of the general formula (VIB-2) undergoes reductive amination reaction with HNR 8 R 9 , and Through further resolution, compounds (VI-2) and (VI-3) are obtained;
- the compound of general formula (VIA) is obtained under metal catalysis to obtain the compound of general formula (VIB-3); the compound of (VIB-3) is subjected to substitution reaction to obtain the compound of general formula (VI-4);
- X is selected from halogen, preferably bromine
- Ring A, R 1 , R 3 , R 8 , R 9 and m are defined as in the general formula (VI-1).
- the present invention provides a kind of preparation method of compound of general formula (IA), described method comprises:
- R 2 and R 3 are as defined in the general formula (I).
- the present invention provides a preparation method of a compound of general formula (IB), the method comprising:
- the bromide (IB-1) compound undergoes a metal-catalyzed cross-coupling reaction (such as Stille coupling reaction) to convert the ethyl ketone intermediate (IB-2) compound; the ethyl ketone intermediate (IB-2) compound is combined with a chiral sulfonic acid
- the imide undergoes a reduction reaction to form a chiral sulfonimide (IB-3) compound; the chiral sulfonimide (IB-3) compound is reduced by sodium borohydride or 9-BBN to give the separable main product (IB -4) and a diastereomeric mixture of the minor product (IB-5); the enantiomer (IB-4) compound was reacted with HCl/1,4-dioxane solution to remove the sulfinyl group, The chiral benzylamine hydrochloride (IB) compound is obtained.
- R 1 , ring A and m are as defined in general formula (I).
- Mass spectrum is obtained by LC/MS instrument, and the ionization mode can be ESI or APCI.
- the thin layer chromatography silica gel plate uses Yantai Huanghai HSGF254 or Qingdao GF254 silica gel plate, the size of the silica gel plate used for thin layer chromatography (TLC) is 0.15mm ⁇ 0.2mm, and the size of the TLC separation and purification products is 0.4mm ⁇ 0.5mm.
- CD3OD Deuterated methanol.
- Nitrogen atmosphere means that the reaction flask is connected to a nitrogen balloon with a volume of about 1 L.
- Test Example 1 Test that the compound of the present invention blocks the binding of SOS1 to KRAS G12C protein
- the following method was used to determine the ability of the compounds of the invention to block the interaction of SOS1 with KRAS G12C protein under in vitro conditions.
- This method uses the KRAS-G12C/SOS1BINDING ASSAY KITS kit (Cat. No. 63ADK000CB16PEG) from Cisbio Company.
- Kit instructions for detailed experimental operation, please refer to the kit instructions.
- Table 1 IC 50 data of the compounds of the present invention blocking the interaction between SOS1 and KRAS G12C protein
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne un dérivé de pyridopyrimidine substitué, son procédé de préparation, et l'utilisation d'une composition pharmaceutique contenant le dérivé en médecine. En particulier, la présente invention concerne un dérivé de pyridopyrimidine substitué représenté par la formule générale (I), un procédé de préparation associé, un sel pharmaceutiquement acceptable de celui-ci, et l'utilisation de ceux-ci en tant qu'agents thérapeutiques, en particulier en tant qu'inhibiteurs de SOS1, la définition de chaque substituant dans la formule générale (I) étant la même que celle dans la description.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202180081504.9A CN116546985A (zh) | 2021-01-28 | 2021-12-03 | 吡啶并嘧啶类衍生物及其制备方法和用途 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110116295 | 2021-01-28 | ||
CN202110116295.9 | 2021-01-28 | ||
CN202110641104 | 2021-06-09 | ||
CN202110641104.0 | 2021-06-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022160931A1 true WO2022160931A1 (fr) | 2022-08-04 |
Family
ID=82652956
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2021/135230 WO2022160931A1 (fr) | 2021-01-28 | 2021-12-03 | Dérivé de pyridopyrimidine, son procédé de préparation et son utilisation |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN116546985A (fr) |
WO (1) | WO2022160931A1 (fr) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11648254B2 (en) | 2021-03-02 | 2023-05-16 | Kumquat Biosciences Inc. | Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling |
WO2024027762A1 (fr) * | 2022-08-05 | 2024-02-08 | 上海艾力斯医药科技股份有限公司 | Composé à cycles fusionnés, son procédé de préparation et son utilisation |
US11912708B2 (en) | 2022-04-20 | 2024-02-27 | Kumquat Biosciences Inc. | Macrocyclic heterocycles and uses thereof |
WO2024074827A1 (fr) | 2022-10-05 | 2024-04-11 | Sevenless Therapeutics Limited | Nouveaux traitements de la douleur |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019122129A1 (fr) * | 2017-12-21 | 2019-06-27 | Boehringer Ingelheim International Gmbh | Nouvelles pyridopyrimidinones à substitution benzylamino et dérivés à utiliser en tant qu'inhibiteurs de sos1 |
CN113801114A (zh) * | 2020-06-11 | 2021-12-17 | 江苏恒瑞医药股份有限公司 | 稠合二环杂芳基类衍生物、其制备方法及其在医药上的应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107400092B (zh) * | 2016-05-20 | 2021-08-24 | 浙江海正药业股份有限公司 | 嘧啶类衍生物及其制备方法和其在医药上的用途 |
JP7219218B2 (ja) * | 2016-12-22 | 2023-02-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規のベンジルアミノ置換キナゾリンおよびsos1阻害剤としての誘導体 |
WO2019027765A1 (fr) * | 2017-08-02 | 2019-02-07 | Northwestern University | Composés de pyrimidine fusionnés substitués et leurs utilisations |
MA56020A (fr) * | 2019-05-31 | 2022-04-06 | Chiesi Farm Spa | Dérivés de pyridopyrimidines utilisés en tant qu'inhibiteurs de p2x3 |
CN116323623A (zh) * | 2020-09-18 | 2023-06-23 | 拜耳公司 | 作为SOS1抑制剂的吡啶并[2,3-d]嘧啶-4-胺 |
CN114539245A (zh) * | 2020-11-26 | 2022-05-27 | 上海翰森生物医药科技有限公司 | 含嘧啶并环类衍生物调节剂、其制备方法和应用 |
-
2021
- 2021-12-03 CN CN202180081504.9A patent/CN116546985A/zh active Pending
- 2021-12-03 WO PCT/CN2021/135230 patent/WO2022160931A1/fr active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019122129A1 (fr) * | 2017-12-21 | 2019-06-27 | Boehringer Ingelheim International Gmbh | Nouvelles pyridopyrimidinones à substitution benzylamino et dérivés à utiliser en tant qu'inhibiteurs de sos1 |
CN113801114A (zh) * | 2020-06-11 | 2021-12-17 | 江苏恒瑞医药股份有限公司 | 稠合二环杂芳基类衍生物、其制备方法及其在医药上的应用 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11648254B2 (en) | 2021-03-02 | 2023-05-16 | Kumquat Biosciences Inc. | Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling |
US11912708B2 (en) | 2022-04-20 | 2024-02-27 | Kumquat Biosciences Inc. | Macrocyclic heterocycles and uses thereof |
WO2024027762A1 (fr) * | 2022-08-05 | 2024-02-08 | 上海艾力斯医药科技股份有限公司 | Composé à cycles fusionnés, son procédé de préparation et son utilisation |
WO2024074827A1 (fr) | 2022-10-05 | 2024-04-11 | Sevenless Therapeutics Limited | Nouveaux traitements de la douleur |
Also Published As
Publication number | Publication date |
---|---|
CN116546985A (zh) | 2023-08-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2022160931A1 (fr) | Dérivé de pyridopyrimidine, son procédé de préparation et son utilisation | |
EP2920183B1 (fr) | Thiéno[3,2-c]pyridin-4(5h)-ones utiles comme inhibiteurs de bet | |
KR20210018204A (ko) | 면역조절제로서 복소환형 화합물 | |
CA3177261A1 (fr) | Compose de benzothiazolyle biaryle, son procede de preparation et son utilisation | |
WO2015127872A1 (fr) | Dérivés de 1,5-diamine phénylène 2,4-disubstitués et leurs applications, compositions pharmaceutiques et compositions pharmaceutiquement acceptables préparées à partir de ces dérivés | |
WO2014140077A1 (fr) | Furopyridines utilisées en tant qu'inhibiteurs de bromodomaine | |
CN111793068A (zh) | 杂芳基化合物和其用途 | |
WO2021143701A1 (fr) | Composé hétérocyclique de pyrimidine-4(3h)-cétone, son procédé de préparation et son utilisation en médecine et en pharmacologie | |
CN111094289B (zh) | 吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用 | |
WO2016173557A1 (fr) | Composé ayant une activité d'inhibition de kinase, procédé de préparation et utilisations | |
KR20170063734A (ko) | Mk2 억제제 및 이의 용도 | |
WO2016011979A1 (fr) | Dérivé 7h-pyrrolo[2,3-d]pyrimidine 2,4-disubstituté, procédé de préparation et utilisation médicinale de ce dernier | |
JP6797923B2 (ja) | Alkおよびsrpk阻害剤ならびに使用方法 | |
CN109721599B (zh) | 一类氨基取代含氮稠环化合物及其制备方法和用途 | |
WO2022135590A1 (fr) | Composés pyrimido-hétérocycliques, et leur procédé de préparation et leur utilisation | |
WO2017101796A1 (fr) | Dérivé de phtalazinone, et procédé de préparation et utilisation associés | |
WO2018010514A1 (fr) | Composé hétérocyclique utilisé en tant qu'inhibiteur de fgfr | |
WO2022170952A1 (fr) | Dérivé de pyridazinone polycyclique servant d'inhibiteur de sos1, son procédé de préparation et son utilisation | |
JP2023538091A (ja) | Btk阻害剤としての複素環式化合物 | |
CN115427035A (zh) | Enl/af9 yeats抑制剂 | |
WO2019085894A1 (fr) | Composé cyclique fusionné contenant de l'azote, son procédé de préparation et son utilisation | |
WO2022105921A1 (fr) | Composé pyrimido-hétérocyclique, son procédé de préparation et son utilisation | |
WO2018205916A1 (fr) | Inhibiteur de fgfr4, préparation et utilisation associées | |
WO2023036252A1 (fr) | Dérivé de pyrrolopyrimidine ou de pyrrolopyridine et son utilisation médicale | |
WO2022127827A1 (fr) | Inhibiteur de mutation de protéine krasg12c et son procédé de préparation, composition pharmaceutique et son application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21922521 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202180081504.9 Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21922521 Country of ref document: EP Kind code of ref document: A1 |